
|Videos|July 24, 2021
Pipeline: Presbyopia, night vision disturbance up next for Vyluma
Advertisement
Presbyopia and night vision disturbance will follow myopia as a clinical focus for Vyluma. Navneet Puri, PhD, the company’s founder, chairman, and CEO, shares what is next.
Newsletter
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
Noninvasive LED light therapy shows long-term safety in early cataract follow-up
2
FDA approves Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for presbyopia
3
When Mites Meet Their Match: Empowering Patients With Targeted Treatment for Demodex Blepharitis
4
MRI study links glymphatic system dysfunction to idiopathic intracranial hypertension
5



























